Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

117.13USD
27 Jun 2017
Change (% chg)

$-1.19 (-1.01%)
Prev Close
$118.32
Open
$118.25
Day's High
$118.51
Day's Low
$117.00
Volume
181,955
Avg. Vol
420,465
52-wk High
$121.75
52-wk Low
$81.13

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $24,823.87
Shares Outstanding(Mil.): 209.80
Dividend: --
Yield (%): --

Financials

  EW.N Industry Sector
P/E (TTM): 39.16 39.14 19.11
EPS (TTM): 3.02 -- --
ROI: 17.30 8.76 -5.00
ROE: 26.05 13.54 -4.24

BRIEF-Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co

* District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc

Jun 16 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 06 2017

BRIEF-Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures

* Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures Source text for Eikon: Further company coverage:

Jun 05 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 05 2017

UPDATE 1-FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 05 2017

FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 05 2017

BRIEF-Edwards Lifesciences Q1 earnings per share $1.06

* Says Q1 earnings per share $1.06; Q1 adjusted earnings per share $0.94; Q1 sales grew 27 percent to $884 million

Apr 25 2017

Edwards profit tops expectations on soaring heart valve sales

Edwards Lifesciences Corp on Tuesday reported higher-than expected first-quarter profit and revenue on surging sales of transcatheter heart valve replacements and raised its full-year earnings forecast to reflect the strong start to the year.

Apr 25 2017

UPDATE 1-Edwards profit tops expectations on soaring heart valve sales

April 25 Edwards Lifesciences Corp on Tuesday reported higher-than expected first-quarter profit and revenue on surging sales of transcatheter heart valve replacements and raised its full-year earnings forecast to reflect the strong start to the year.

Apr 25 2017

Edwards profit tops expectations on soaring heart valve sales

April 25 Edwards Lifesciences Corp on Tuesday reported higher-than expected first-quarter profit and revenue on surging sales of transcatheter heart valve replacements, and raised its full-year earnings forecast to reflect the strong start to the year.

Apr 25 2017

More From Around the Web

Earnings vs. Estimates